Abstract
Aim: To evaluate whether the results of chemosensitivity testing were associated with prognosis of colorectal cancer patients after adjuvant 5-fluorouracil (FU)/ leucovorin chemotherapy. Patients and Methods: Eighty-nine patients who received 5-FU/leucovorin adjuvant chemotherapy for colorectal cancer were enrolled. Chemosensitivity tests were performed and tumor growth inhibition rate was calculated using the MTT (3-(4,5-dimethylthiazol-2-yl)02,5-diphenyl-2H tetrazolium bromide) assay. Results: Fifty-one patients (57.3%) were sensitive to 5-FU according to the chemosensitivity test. After a median follow-up of 64 months, there was a significant difference between the 5-year disease-free survival rates of the chemosensitive and chemo-resistant groups. However, there was no significant difference in the overall 5-year survival between the chemo-sensitive and chemo-resistant groups. Conclusion: A positive 5-FU sensitivity test with in vitro histoculture drug response assay (HDRA) was associated with better diseasefree survival. Chemosensitivity may be a prognostic factor for colorectal cancer patients undergoing adjuvant 5-FU/ leucovorin chemotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 2679-2682 |
| Number of pages | 4 |
| Journal | Anticancer Research |
| Volume | 37 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2017 May 1 |
Fingerprint
Keywords
- 5-fluorouracil
- Chemosensitivity
- Chemotherapy
- Colorectal cancer
- Survival
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Clinical significance of 5-fluorouracil chemosensitivity testing in patients with colorectal cancer. / Ji, Woong Bae; Um, Jun Won; Ryu, Je Seock; Hong, Kwang Dae; Kim, Jung Sik; Min, Byung Wook; Joung, Sung Yeop; Lee, Ju-Han; Kim, Young Sik.
In: Anticancer Research, Vol. 37, No. 5, 01.05.2017, p. 2679-2682.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical significance of 5-fluorouracil chemosensitivity testing in patients with colorectal cancer
AU - Ji, Woong Bae
AU - Um, Jun Won
AU - Ryu, Je Seock
AU - Hong, Kwang Dae
AU - Kim, Jung Sik
AU - Min, Byung Wook
AU - Joung, Sung Yeop
AU - Lee, Ju-Han
AU - Kim, Young Sik
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Aim: To evaluate whether the results of chemosensitivity testing were associated with prognosis of colorectal cancer patients after adjuvant 5-fluorouracil (FU)/ leucovorin chemotherapy. Patients and Methods: Eighty-nine patients who received 5-FU/leucovorin adjuvant chemotherapy for colorectal cancer were enrolled. Chemosensitivity tests were performed and tumor growth inhibition rate was calculated using the MTT (3-(4,5-dimethylthiazol-2-yl)02,5-diphenyl-2H tetrazolium bromide) assay. Results: Fifty-one patients (57.3%) were sensitive to 5-FU according to the chemosensitivity test. After a median follow-up of 64 months, there was a significant difference between the 5-year disease-free survival rates of the chemosensitive and chemo-resistant groups. However, there was no significant difference in the overall 5-year survival between the chemo-sensitive and chemo-resistant groups. Conclusion: A positive 5-FU sensitivity test with in vitro histoculture drug response assay (HDRA) was associated with better diseasefree survival. Chemosensitivity may be a prognostic factor for colorectal cancer patients undergoing adjuvant 5-FU/ leucovorin chemotherapy.
AB - Aim: To evaluate whether the results of chemosensitivity testing were associated with prognosis of colorectal cancer patients after adjuvant 5-fluorouracil (FU)/ leucovorin chemotherapy. Patients and Methods: Eighty-nine patients who received 5-FU/leucovorin adjuvant chemotherapy for colorectal cancer were enrolled. Chemosensitivity tests were performed and tumor growth inhibition rate was calculated using the MTT (3-(4,5-dimethylthiazol-2-yl)02,5-diphenyl-2H tetrazolium bromide) assay. Results: Fifty-one patients (57.3%) were sensitive to 5-FU according to the chemosensitivity test. After a median follow-up of 64 months, there was a significant difference between the 5-year disease-free survival rates of the chemosensitive and chemo-resistant groups. However, there was no significant difference in the overall 5-year survival between the chemo-sensitive and chemo-resistant groups. Conclusion: A positive 5-FU sensitivity test with in vitro histoculture drug response assay (HDRA) was associated with better diseasefree survival. Chemosensitivity may be a prognostic factor for colorectal cancer patients undergoing adjuvant 5-FU/ leucovorin chemotherapy.
KW - 5-fluorouracil
KW - Chemosensitivity
KW - Chemotherapy
KW - Colorectal cancer
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85019107873&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019107873&partnerID=8YFLogxK
U2 - 10.21873/anticanres.11616
DO - 10.21873/anticanres.11616
M3 - Article
VL - 37
SP - 2679
EP - 2682
JO - The BMJ
JF - The BMJ
SN - 0730-6512
IS - 5
ER -